153 related articles for article (PubMed ID: 1666824)
1. A comparative test of fifteen compounds against all known human rhinovirus serotypes as a basis for a more rational screening program.
Andries K; Dewindt B; Snoeks J; Willebrords R; Stokbroekx R; Lewi PJ
Antiviral Res; 1991 Oct; 16(3):213-25. PubMed ID: 1666824
[TBL] [Abstract][Full Text] [Related]
2. Two groups of rhinoviruses revealed by a panel of antiviral compounds present sequence divergence and differential pathogenicity.
Andries K; Dewindt B; Snoeks J; Wouters L; Moereels H; Lewi PJ; Janssen PA
J Virol; 1990 Mar; 64(3):1117-23. PubMed ID: 2154596
[TBL] [Abstract][Full Text] [Related]
3. Antiviral capsid-binding compounds can inhibit the adsorption of minor receptor rhinoviruses.
Dewindt B; van Eemeren K; Andries K
Antiviral Res; 1994 Sep; 25(1):67-72. PubMed ID: 7811059
[TBL] [Abstract][Full Text] [Related]
4. VP1 sequencing of all human rhinovirus serotypes: insights into genus phylogeny and susceptibility to antiviral capsid-binding compounds.
Ledford RM; Patel NR; Demenczuk TM; Watanyar A; Herbertz T; Collett MS; Pevear DC
J Virol; 2004 Apr; 78(7):3663-74. PubMed ID: 15016887
[TBL] [Abstract][Full Text] [Related]
5. Binding affinities of structurally related human rhinovirus capsid-binding compounds are related to their activities against human rhinovirus type 14.
Fox MP; McKinlay MA; Diana GD; Dutko FJ
Antimicrob Agents Chemother; 1991 Jun; 35(6):1040-7. PubMed ID: 1656851
[TBL] [Abstract][Full Text] [Related]
6. Conformationally restricted analogues of disoxaril: a comparison of the activity against human rhinovirus types 14 and 1A.
Mallamo JP; Diana GD; Pevear DC; Dutko FJ; Chapman MS; Kim KH; Minor I; Oliveira M; Rossmann MG
J Med Chem; 1992 Dec; 35(25):4690-5. PubMed ID: 1335081
[TBL] [Abstract][Full Text] [Related]
7. A novel basis of capsid stabilization by antiviral compounds.
Phelps DK; Post CB
J Mol Biol; 1995 Dec; 254(4):544-51. PubMed ID: 7500332
[TBL] [Abstract][Full Text] [Related]
8. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes.
Matthews DA; Dragovich PS; Webber SE; Fuhrman SA; Patick AK; Zalman LS; Hendrickson TF; Love RA; Prins TJ; Marakovits JT; Zhou R; Tikhe J; Ford CE; Meador JW; Ferre RA; Brown EL; Binford SL; Brothers MA; DeLisle DM; Worland ST
Proc Natl Acad Sci U S A; 1999 Sep; 96(20):11000-7. PubMed ID: 10500114
[TBL] [Abstract][Full Text] [Related]
9. Comparative studies on the antirhinovirus activity and the mode of action of the rhinovirus capsid binding agents, chalcone amides.
Ninomiya Y; Shimma N; Ishitsuka H
Antiviral Res; 1990 Feb; 13(2):61-74. PubMed ID: 2160796
[TBL] [Abstract][Full Text] [Related]
10. Human rhinovirus 3 at 3.0 A resolution.
Zhao R; Pevear DC; Kremer MJ; Giranda VL; Kofron JA; Kuhn RJ; Rossmann MG
Structure; 1996 Oct; 4(10):1205-20. PubMed ID: 8939746
[TBL] [Abstract][Full Text] [Related]
11. A model for compounds active against human rhinovirus-14 based on X-ray crystallography data.
Diana GD; Treasurywala AM; Bailey TR; Oglesby RC; Pevear DC; Dutko FJ
J Med Chem; 1990 May; 33(5):1306-11. PubMed ID: 2158559
[TBL] [Abstract][Full Text] [Related]
12. Selective human enterovirus and rhinovirus inhibitors: An overview of capsid-binding and protease-inhibiting molecules.
Shih SR; Chen SJ; Hakimelahi GH; Liu HJ; Tseng CT; Shia KS
Med Res Rev; 2004 Jul; 24(4):449-74. PubMed ID: 15170592
[TBL] [Abstract][Full Text] [Related]
13. Structure-based drug design of antirhinoviral compounds.
Giranda VL
Structure; 1994 Aug; 2(8):695-8. PubMed ID: 7994569
[TBL] [Abstract][Full Text] [Related]
14. VP4 protein from human rhinovirus 14 is released by pressure and locked in the capsid by the antiviral compound WIN.
Gonçalves RB; Mendes YS; Soares MR; Katpally U; Smith TJ; Silva JL; Oliveira AC
J Mol Biol; 2007 Feb; 366(1):295-306. PubMed ID: 17161425
[TBL] [Abstract][Full Text] [Related]
15. SCH 38057: a picornavirus capsid-binding molecule with antiviral activity after the initial stage of viral uncoating.
Rozhon E; Cox S; Buontempo P; O'Connell J; Slater W; De Martino J; Schwartz J; Miller G; Arnold E; Zhang A
Antiviral Res; 1993 May; 21(1):15-35. PubMed ID: 8391247
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity.
Andries K; Dewindt B; Snoeks J; Willebrords R; van Eemeren K; Stokbroekx R; Janssen PA
Antimicrob Agents Chemother; 1992 Jan; 36(1):100-7. PubMed ID: 1317142
[TBL] [Abstract][Full Text] [Related]
17. Lack of quantitative correlation between inhibition of replication of rhinoviruses by an antiviral drug and their stabilization.
Andries K; Dewindt B; Snoeks J; Willebrords R
Arch Virol; 1989; 106(1-2):51-61. PubMed ID: 2548460
[TBL] [Abstract][Full Text] [Related]
18. Structural studies on human rhinovirus 14 drug-resistant compensation mutants.
Hadfield AT; Oliveira MA; Kim KH; Minor I; Kremer MJ; Heinz BA; Shepard D; Pevear DC; Rueckert RR; Rossmann MG
J Mol Biol; 1995 Oct; 253(1):61-73. PubMed ID: 7473717
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and antirhinovirus activity of 3-(diethylamino)-5-phenylisoxazole derivatives.
Mazzei M; Garzoglio R; Balbi A; Grandi T; De Montis A; Corrias S; La Colla P
Farmaco; 1996 May; 51(5):351-9. PubMed ID: 8767845
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and in vitro evaluation of novel chroman-4-one, chroman, and 2H-chromene derivatives as human rhinovirus capsid-binding inhibitors.
Conti C; Proietti Monaco L; Desideri N
Bioorg Med Chem; 2011 Dec; 19(24):7357-64. PubMed ID: 22088306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
